What is Stuart Therapeutics?
Stuart Therapeutics, established in 2017 and headquartered in Stuart, Florida, is a pre-clinical stage pharmaceutical company. Its core focus is the development of PolyCol, a novel therapeutic platform based on collagen mimetic peptides. This innovative approach targets unmet needs within the pharmaceutical landscape, positioning Stuart Therapeutics as a key player in peptide-based therapeutics.
How much funding has Stuart Therapeutics raised?
Stuart Therapeutics has raised a total of $11M across 1 funding round:
Series A
$11M
Series A (2021): $11M with participation from BioBrit , LLC, MiMo Capital LLC, InFocus Capital Partners LLC, and Wisconsin Alumni Research Foundation
Key Investors in Stuart Therapeutics
BioBrit , LLC
An undisclosed investor participating in the funding round.
MiMo Capital LLC
An undisclosed investor participating in the funding round.
Wisconsin Alumni Research Foundation
The Wisconsin Alumni Research Foundation (WARF) is an independent, nonprofit foundation that manages the intellectual property arising from research at the University of Wisconsin Madison and affiliated institutes, focusing on patenting and licensing university discoveries.
What's next for Stuart Therapeutics?
The recent major strategic investment provides Stuart Therapeutics with substantial backing to advance its PolyCol platform through critical pre-clinical development phases. This capital infusion is expected to accelerate research and development, potentially paving the way for future clinical trials and commercialization, solidifying its position in the competitive biotech sector.
See full Stuart Therapeutics company page
